Stay updated on Pembrolizumab + Imprime PGG in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Imprime PGG in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab + Imprime PGG in NSCLC Clinical Trial page
- Check7 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check14 days agoChange DetectedThe footer now displays site revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check21 days agoNo Change Detected
- Check34 days agoChange DetectedThe page now shows a 403 Forbidden error with a simple header and a Home button, indicating access is blocked. As a result, the study details that would normally appear on the page are not accessible.SummaryDifference20%

- Check56 days agoChange DetectedUpdate to the page revision shows the record now using v3.6.6, representing a revision bump in the page metadata. The previous v3.6.5 revision was removed, indicating only an internal update rather than changes to the study data.SummaryDifference0.1%

- Check77 days agoChange DetectedThe page now shows Revision: v3.6.5, replacing v3.6.4. This appears to be a minor system revision that does not change the study information or user-facing content.SummaryDifference0.0%

- Check91 days agoChange DetectedThe page's revision label was updated from v3.6.3 to v3.6.4, representing a new revision of the page content.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab + Imprime PGG in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Imprime PGG in NSCLC Clinical Trial page.